NetraMark's AI Platform Shows Promise in Precision Psychiatry with Enhanced Clinical Trial Design
Key Insights
NetraMark presented two significant applications of its NetraAI technology at major psychiatric conferences, demonstrating enhanced clinical trial designs for major depressive disorder (search) treatments.
The AI platform successfully distinguished true ketamine pharmacologic effects from placebo responses, showing complete separation between responder groups by the second infusion with 91% prediction accuracy.
NetraAI identified genetic biomarkers through hypomethylation patterns at three gene sites linked to neuroplasticity, offering biological insights into treatment response mechanisms.
NetraMark Holdings Inc. (search) presented breakthrough applications of its artificial intelligence platform at two major psychiatric conferences, showcasing how AI-driven precision analytics can transform clinical trial design for major depressive disorder (search) (MDD) treatments. The presentations at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn conference and the European College of Neuropsychopharmacology (ECNP) Congress demonstrated the power of NetraAI technology in addressing long-standing challenges in CNS drug development.
Distinguishing True Drug Effects from Placebo Response
NetraMark's first presentation analyzed data from a randomized, crossover trial of ketamine in treatment-resistant depression (search), revealing that ketamine responders had distinct baseline characteristics compared to placebo responders. The analysis showed that separation between groups became clearer with repeated dosing, while within-group consistency also strengthened.
In the Phase II ketamine trial, NetraAI revealed dramatic changes in responder patterns. Cross-group divergence between ketamine and placebo responder personas increased from 0.75 (moderate) after the first infusion to 1.0 (complete separation) by the second infusion. Simultaneously, within-group cohesion for ketamine responders rose from 25% after infusion 1 to approximately 67% after infusion 2, demonstrating that responders became more internally consistent with repeated treatment.
These findings indicate that ketamine's efficacy is not simply the result of functional unblinding and that distinct patient subtypes were driving response. The results point to new opportunities for persona-guided trial enrichment, stratified randomization, and patient selection strategies in clinical practice.
Genetic Biomarkers Predict Treatment Response
The second presentation introduced NetraMark's novel algorithm to data from the CAN-BIND trial of escitalopram, addressing the challenge of heterogeneous MDD populations where traditional machine learning approaches struggled with prediction accuracy. NetraAI identified a compact, reproducible feature set related to anhedonia and mood that improved the prediction of treatment response.
The platform reduced clinical variables from 718 to 8 key variables covering anhedonia, daily functioning, appetite, and negative thinking. With the "unknown" class introduced, 26 non-responders, 23 responders, and 124 unknowns were identified, leading to improved classifier performance.
Among 169 patients with approximately 68,600 methylation variables each, NetraAI identified 33 of 117 responders as Highly Predictive Responders (HPRs). The analysis uncovered a highly predictive responder subgroup defined by hypomethylation at three gene sites: LINC01580 (search), STK24 (search), and ATXN7L3 (search), linked to neuroplasticity. These genetic signatures predicted HPRs whose treatment success could be forecast with 91% accuracy when traditional classifiers were retrained on these features.
Mechanistic Insights into Treatment Response
The identified genes support synaptic remodeling, chromatin plasticity, and hippocampal neurogenesis, offering a biological explanation for treatment response. These mechanistic insights demonstrate the algorithm's potential to boost predictive accuracy, improve trial interpretability, and advance precision psychiatry by defining clinically meaningful subgroups.
"The ability to distinguish true pharmacologic effects from placebo and to predict treatment response with explainable subgroups represents a meaningful advancement," said Josh Spiegel, President at NetraMark. "These findings demonstrate how our technology can transform the way psychiatric and CNS trials are designed, interpreted, and translated into clinical practice."
Advancing Precision Medicine in CNS Development
NetraMark's AI-driven methodologies demonstrate how explainable machine learning can reshape CNS clinical research. By enabling sharper patient stratification, reducing placebo-related noise, and improving predictive modeling, these approaches support more targeted and efficient clinical trials.
NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. The platform uses explainable subsets to derive insights and hypotheses, including factors that influence treatment and placebo responses, as well as adverse events, that can significantly increase the chances of clinical trial success.
As precision medicine becomes central to drug development, NetraMark's innovations provide pharmaceutical companies and researchers with a powerful toolkit to uncover meaningful patient subgroups, accelerate development timelines, and gain deeper insight into psychiatric disorders and treatment response.